Madrigal Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Madrigal Pharmaceuticals Inc MDGL.OQ reported a quarterly adjusted loss of $2.71​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-5.68. The mean expectation of fourteen analysts for the quarter was for a loss of $4.24 per share. Wall Street expected results to range from $-5.53 to $-3.44 per share.

• Revenue was $103.32 million​; analysts expected $98.56 million.

• Madrigal Pharmaceuticals Inc's reported EPS for the quarter was a loss of $2.71​.

• The company reported a quarterly loss of $59.42 million.

• Madrigal Pharmaceuticals Inc shares had risen by 0.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.2% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $394.00

This summary was machine generated from LSEG data February 26 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)